This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: CNBC
Susannah Rosen was diagnosed with a KIF1A gene mutation at the age of 2½. Patients diagnosed with severe KIF1A gene mutations may live only into early childhood, while patients with mild symptoms can live beyond their 20s. Because it's a progressive neurodegenerative disease, symptoms such as intellectual and muscular disabilities worsen over time. In 2016, when Susannah Rosen was 2½ years old, her parents, Luke Rosen and Sally Jackson, noticed during bath time that something wasn't right. When Sally prompted Susannah to playfully kick her legs in the water, she wasn't able to. “For our first kid, if it was a bee sting, we would run into the emergency room, right? But we were like, she's our second kid, you know? She's gonna catch up on her own ... but she didn't catch up,” Luke said. “After we found out she couldn't kick, we went to the hospital.” Luke and Sally were living with their two kids in New York City. Luke had a thriving career as an actor and writer, and Sally w
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.MarketBeat
- Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)Business Wire
- Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]Yahoo! Finance
- Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readoutsBusiness Wire
IONS
Earnings
- 10/29/25 - Beat
IONS
Sec Filings
- 1/30/26 - Form 144
- 1/30/26 - Form 144
- 1/30/26 - Form 144
- IONS's page on the SEC website